[1] |
Zhang S, Mercado-Uribe I, Xing Z, et al. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells[J]. Oncogene, 2014,33(1):116-128. DOI: 10.1038/onc.2013.96.
doi: 10.1038/onc.2013.96
|
[2] |
Coward J, Harding A. Size does matter: why polyploid tumor cells are critical drug targets in the war on cancer[J]. Front Oncol, 2014,4:123. DOI: 10.3389/fonc.2014.00123.
doi: 10.3389/fonc.2014.00123
pmid: 24904834
|
[3] |
Amend SR, Torga G, Lin KC, et al. Polyploid giant cancer cells: unrecognized actuators of tumorigenesis, metastasis, and resistance[J]. Prostate, 2019,79(13):1489-1497. DOI: 10.1002/pros.23877.
doi: 10.1002/pros.23877
pmid: 31376205
|
[4] |
杜均祥, 彭东旭, 潘莹, 等. Tau低表达对肺腺癌患者多西他赛化疗敏感性及疾病进展时间关系的研究[J]. 临床肺科杂志, 2019,24(6):1111-1115. DOI: 10.3969/j.issn.1009-6663.2019.06.037.
|
[5] |
鲁凯, 刘燕文, 李惠, 等. BRCA1在乳腺癌中的表达及与多西他赛疗效的关系[J]. 中华内分泌外科杂志, 2016,10(5):382-385. DOI: 10.3760/cma.j.issn.1674-6090.2016.05.008.
|
[6] |
Ishida S, Masuguchi K, Kawashiri T, et al. Effects of diluent volume and administration time on the incidence of anaphylaxis following docetaxel therapy in breast cancer[J]. Biol Pharm Bull, 2020,43(4):663-668. DOI: 10.1248/bpb.b19-00876.
doi: 10.1248/bpb.b19-00876
pmid: 32238707
|
[7] |
于卉影, 孙英慧, 蔺迪, 等. 肿瘤患者自体CIK细胞输注增强再次制备时CD3+CD56+细胞的体外扩增能力 [J]. 细胞与分子免疫学杂志, 2014,30(7):748-753, 758.
|
[8] |
李淑青, 陈亚萍. 卵巢癌对顺铂和紫杉醇耐药的分子机制[J]. 国际妇产科学杂志, 2016,43(2):145-150.
|
[9] |
张赛, 邱明宁, 汤焕城, 等. 去势抵抗性前列腺癌发生多西他赛耐药的相关机制及其治疗进展[J]. 肿瘤, 2016,36(10):1165-1170. DOI: 10.3781/j.issn.1000-7431.2016.55.436.
|
[10] |
Ogden A, Rida PC, Knudsen BS, et al. Docetaxel-induced polyploidization may underlie chemoresistance and disease relapse[J]. Cancer Lett, 2015,367(2):89-92. DOI: 10.1016/j.canlet.2015.06.025.
doi: 10.1016/j.canlet.2015.06.025
pmid: 26185000
|
[11] |
Tsubaki M, Takeda T, Ogawa N, et al. Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells[J]. Leuk Res, 2015,39(4):445-452. DOI: 10.1016/j.leukres.2015.01.016.
doi: 10.1016/j.leukres.2015.01.016
pmid: 25726084
|
[12] |
Mittal K, Donthamsetty S, Kaur R, et al. Multinucleated polyploidy drives resistance to docetaxel chemotherapy in prostate cancer[J]. Br J Cancer, 2017,116(9):1186-1194. DOI: 10.1038/bjc.2017.78.
doi: 10.1038/bjc.2017.78
pmid: 28334734
|
[13] |
Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis[J]. Mol Oncol, 2017,11(1):28-39. DOI: 10.1002/1878-0261.12017.
doi: 10.1002/1878-0261.12017
pmid: 28085222
|
[14] |
Mittal V. Epithelial mesenchymal transition in tumor metastasis[J]. Annu Rev Pathol, 2018,13:395-412. DOI: 10.1146/annurev-pathol-020117-043854.
doi: 10.1146/annurev-pathol-020117-043854
pmid: 29414248
|
[15] |
Papadaki MA, Stoupis G, Theodoropoulos PA, et al. Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metasta-tic breast cancer[J]. Mol Cancer Ther, 2019,18(2):437-447. DOI: 10.1158/1535-7163.MCT-18-0584.
doi: 10.1158/1535-7163.MCT-18-0584
pmid: 30401696
|
[16] |
van Staalduinen J, Baker D, Ten Dijke P, et al. Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?[J]. Oncogene, 2018,37(48):6195-6211. DOI: 10.1038/s41388-018-0378-x.
doi: 10.1038/s41388-018-0378-x
pmid: 30002444
|
[17] |
Schmeel LC, Schmeel FC, Coch C, et al. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international re-gistry on CIK cells (IRCC)[J]. J Cancer Res Clin Oncol, 2015,141(5):839-849. DOI: 10.1007/s00432-014-1864-3.
doi: 10.1007/s00432-014-1864-3
pmid: 25381063
|
[18] |
Introna M. CIK as therapeutic agents against tumors[J]. J Autoi-mmun, 2017,85:32-44. DOI: 10.1016/j.jaut.2017.06.008.
|
[19] |
梁雪峰, 郑振东, 朴瑛, 等. 自体CIK细胞治疗联合 DP 方案一线化疗治疗晚期肺腺癌临床研究[J]. 肿瘤预防与治疗, 2013,26(2):68-71. DOI: 10.3969/j.issn.1674-0904.2013.02.003.
|
[20] |
李宁, 田永巍, 高岭, 等. 自体CIK细胞联合放化疗治疗中晚期子宫颈癌的疗效[J]. 中国肿瘤生物治疗杂志, 2016,23(6):830-834. DOI: 10.3872/j.issn.1007-385X.2016.06.016.
|